{
  "ticker": "QTTB",
  "company_name": "Q32 Bio Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06018428",
      "title": "A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Alopecia Areata",
      "start_date": "2023-09-12",
      "completion_date": "2026-09",
      "enrollment": 0,
      "sponsor": "Q32 Bio Inc."
    },
    {
      "nct_id": "NCT05509023",
      "title": "Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Atopic Dermatitis",
      "start_date": "2022-09-30",
      "completion_date": "2024-12",
      "enrollment": 0,
      "sponsor": "Q32 Bio Inc."
    },
    {
      "nct_id": "NCT04485481",
      "title": "Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Safety Issues",
      "start_date": "2020-09-08",
      "completion_date": "2022-01-12",
      "enrollment": 0,
      "sponsor": "Q32 Bio Inc."
    },
    {
      "nct_id": "NCT06419205",
      "title": "A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G",
      "status": "WITHDRAWN",
      "phase": "PHASE2",
      "condition": "IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy",
      "start_date": "2024-06-27",
      "completion_date": "2026-06",
      "enrollment": 0,
      "sponsor": "Q32 Bio Inc."
    }
  ],
  "summary": {
    "total_trials": 4,
    "by_phase": {
      "PHASE2": 3,
      "PHASE1": 1
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 2,
      "COMPLETED": 1,
      "WITHDRAWN": 1
    },
    "active_trials": 2,
    "completed_trials": 1,
    "conditions": [
      "Alopecia Areata",
      "Atopic Dermatitis",
      "IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy",
      "Safety Issues"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T13:12:14.161222",
    "search_query": "Q32 Bio Inc.",
    "url": "https://clinicaltrials.gov/search?term=Q32+Bio+Inc."
  }
}